VBI Vaccines — Investor Presentation (March 2018)
34 slides from VBI Vaccines's investor presentation, Mar 14, 2018
Slide 1: VBI Vaccines Corporate Presentation March 2018
{> VBI VACCINES CORPORATE 7 : NASDAQ: VBIV MARCH 2018
Slide 2: Cautionary Statement Regarding Forward-Looking Information
Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe horbor provisions of the Private Securities Litigation Reform Act of 1995 an
Slide 3: 1. Introduction to VBI Vaccines
ty, S 1. Introduction to VBI Vaccines CTS NASDAQ: VBIV 3
Slide 4: VBI Vaccines Global Footprint
VBI Vaccines Global Footprint HEADQUARTERS ~ CAMBRIDGE, MA " CEO, CSO, CBO + 3 FTEs =~ Central location in biotechnology hub RESEARCH OPERATIONS - OTTAWA, CANADA = CMO, Finance +~25 FTEs = World-class R&D team and facility MANUFACTURING FACILITY - REHOVOT, ISRAEL = 65 FTEs = GMP manufacturing facili
Slide 5: VBI Vaccines Leadership
VBI Vaccines Leadership MANAGEMENT LS Jeff Baxter @D Esevwn A ie at President & CEO crerminine GROUP Chief Medical Officer Dr. David Anderson, Ph.D. gy riarvaRD Nell Beattie ARTISAN Chief Scientific Officer meres Chief Business Officer i Tw Soa of usinss BOARD OF DIRECTORS Dr. Steven Gillis NN a ARC
Slide 6: VBI Vaccines Pipeline
VBI Vaccines Pipeline Multiple Opportunities in Infec! us Disease and Oncology LEAD PRE-CLINICAL PHASE! PHASE PHASEIII_ APPROVED STATUS INFECTIOUS DISEASE Enrolling Phase Ill ‘Sci-B-Vac® (Hepatitis B) Headline Ph Ill data (Licensed in 15 countries) expected mid-2019 Final Ph I data — a Preclinical w
Slide 7: Recent Key Achievements
Recent Key Achievements DECEMBER 2016 - MARCH 2018 January 2018 December 2017 October 2017 August 2017 ‘August 2017 July 2017 July 2017 June 2017 December 2016 First GBM patient dosed in Phase I/Ila clinical study of VBI-1901 First subject vaccinated in Phase III clinical program for Sci-B-Vac® (Hep
Slide 8: 2. Sci-B-Vac: Hepatitis B
A 2. Sci-B-Vac®: Hepatitis B Y Zim NASDAQ: VBIV 8
Slide 9: Hepatitis B Unmet Need
———————— EE Hepatitis B Unmet Need Reported US Hepatitis B Va in Coverage — 2015. (23 doses) Otherwise Healthy Adults aged > 19 years 24.6% Adults aged 19-49 years 32.0% Adults age > 50 years 16.5% High-Risk Chronic Liver Conditions 27.4% Diabetics — Age 19-59 years 24.4% Diabetics - Age 2 60 years
Slide 10: Existing High Unmet Need in Specific Populations
———————— EE Existing High Unmet Need in Specific Populations SEROCONVERSION RATES WITH CURRENT VACCINES FALL DRAMATICALLY WITHIN THE ELDERLY AND HIGH-RISK PATIENT POPULATIONS Anti-HBs Seroconversion Rates After Hepat B Vaccination Neonates >95% Age 2-19 ~99% Age 20 - 29 ~95% Age 30 - 39 ~90% ‘Age 40
Slide 11: Sci-B-Vac Overview
Sci-B-Vac® Overview ONLY COMMERCIAL HBV VACCINE KNOWN TO MIMIC ALL THREE VIRAL SURFACE ANTIGENS — ALREADY SAFELY USED IN 500,000+ PATIENTS * Sci-B-Vac® achieves rapid onset of protection, with high levels of anti-HBV antibodies (HBsAb), at a lower dosage than competing vaccines 2N GENERATION VACCINE
Slide 12: Sci-B-Vac Existing Safety and Efficacy Data Package
———————— EE Sci-B-Vac® Existing Safety and Efficacy Data Package EXTENSIVE CLINICAL DEVELOPMENT SUPPORTS PHASE III DESIGN * Product distribution data globally estimates that over 500,000 infants and adults have been vaccinated with Sci-B-Vac® * Inthe last two decades, 22 clinical trials have been co
Slide 13: Sci-B-Vac Demonstrated Superior Seroprotection Rates in Older Adults
Sci-B-Vac® Demonstrated Superior Seroprotection Rates in Older Adults Stratification by Age of Study 38-96-040 Demonstrates Significantly Improved Potency in Older Adults Seroprotection Stratified by Age 100.0% 96.6%. . 0.0% EngerixB-<=45 (n=136) —EngerixB>45 (n=115) —SchBVace=45(n=118) ——_Sc-B-Vac>
Slide 14: Interim Data from Israeli Phase IV Study Reinforces Sci-B-Vac Potency
Interim Data from Israeli Phase IV Study Reinforces Strength of Sci- B-Vac® Potency in Adult Populations & Potential for Rapid Seroprotection 100% 80% 60% 40% 20% 0% ‘SCI-B-VAC® PHASE IV STUDY IN ISRAELI ADULTS (AGE 18-40, N=88) SEROPROTECTION (>10 IU/ML) 98.8% 91.9% Month 1 Month 2 Month 3 30-days
Slide 15: Phase III Clinical Program
SaaS SSS...aQg Phase III Clinical Program * Target Population: ~4,800 adults age 18 years and older + Expected Duration: 15 Months * Clinical Trial Sites: ~40 sites across the US, Europe, and Canada * Design: Two concurrent Phase III studies: 1. PROTECT : Safety and immunogenicity study (n=1,600) 2.
Slide 16: 3. eVLP Portfolio Programs
ee S 3. eVLP Portfolio Programs S CMSs NASDAQ: VBIV 6
Slide 17: eVLPs are a 3rd-Generation Class of Synthetic Vaccines
eVLPs are a 3'-Generation Class of Synthetic Vaccines = eVLPs are the same size and structure as enveloped viruses; present antigens in their natural state for an improved immune response = The foundation of the eVLP Platform is a stable, protein-based core on which additional vaccine antigens of in
Slide 18: 3. eVLP Portfolio Programs: a. CMV
ty, S 3. eVLP Portfolio Programs a. CMV CMSs NASDAQ: VBIV 8
Slide 19: Congenital CMV is a Leading Public Health Priority
Congenital CMV is a Leading Public Health Priority U.S. CHILDREN BORN WITH OR DEVELOPING LONG-TERM MEDICAL CONDITIONS Congenital CMV Disease Fetal Alcohol Syndrome Down Syndrome Spina Bifida / Anencephaly _ CMV affects more live births Pediatric HIV / AIDS than Down Syndrome or Fetal Alcohol Syndrom
Slide 20: Congenital CMV is a Leading Public Health Priority
Congenital CMV is a Leading Public Health Priority = Each year, approximately 30,000 infants are born with CMV infection, of which 5,000+ U.S. infants will develop permanent problems including deafness, blindness, and developmental delays = Inthe U.S., the direct economic costs of CMV infection exce
Slide 21: eVLP Presentation Improves CMV Vaccine Potency
eVLP Presentation Improves CMV Vaccine Potency Presentation of gB antigen in an eVLP improves relevant functional CMV neutralizing responses relative to recombinant gB protein PRECLINICAL RESULTS Neutralizing antibody titers for mice immunized _. ak with comparable doses of Recombinant gB of * Neutr
Slide 22: CMV Phase I Clinical Study Overview
CMV Phase | Clinical Study Overview Opportunity for Immunologic Human Proof of Concept with Ph | Data STUDY DESIGN * Target Population: 128 CMV-Negative Healthy Adults (18-40 yrs) * Design: Staggered Enrollment with Vaccinations at 0, 2, and 6 Months * Duration: 20 Months * Interim Data Read-Out: Ba
Slide 23: Interim Phase I Immunogenicity Signals (1)
Interim Phase | Immunogenicity Signals (1) BASED ON SUBJECT SAMPLES COLLECTED 1 MONTH AFTER 2NP VACCINATION After two vaccinations, immunization of subjects with the highest dose of VBI-1501A (2.0ug) induced: * Seroconversion* in 100% of 1 subjects 1 + Adjuvant (alum) enhances jeonae ° % immunogenic
Slide 24: Interim Phase I Immunogenicity Signals (2)
Interim Phase | Immunogenicity Signals (2) BASED ON SUBJECT SAMPLES COLLECTED 1 MONTH AFTER 2NP VACCINATION Clear dose-dependent boosting of response: 25: 20: Fold-increase is based on comparison of antibody binding GMTs at day 56 (post 1 vaccination) vs. 10- day 84 (1 month post 2"4 vaccination) Fo
Slide 25: Interim Phase I Data Summary
Interim Phase | Data Summary * VBI-1501A is safe and well tolerated at all doses tested * VBI-1501A is immunogenic after 2 doses © Evidence of strong boosting in antibody titers observed, which is dose-dependent © Observed neutralizing antibodies against epithelial cell infection in some subjects is
Slide 26: 3. eVLP Portfolio Programs: b. GBM
ty, S 3. eVLP Portfolio Programs b. GBM NASDAQ: VBIV 6
Slide 27: Therapeutic GBM Candidate Builds on Prophylactic CMV Candidate
Therapeutic GBM Candidate Builds on Prophylactic CMV Candidate (VBI-1501A) by Adding an Internal pp65 Protein to ici 88 Envelope p65 ‘Foreign’ Elicit a Th1 Response C Pda yet oat wes Toei! Monovalent gB for Belem PDED fot Attributes 4 Therapeutic Immuno- Prophylaxis Oncology Present antigen in natur
Slide 28: Poor Immunogenicity of Traditional Tumor-Associated Antigens
Poor Immunogenicity of Traditional Tumor-Associated Antigens (TAAs) has Limited Past Therapeutic Cancer Vaccines IMMUNOGENICITY LOW VIRAL CMV ANTIGENS ARE OVER-EXPRESSED (>90%) IN MULTIPLE SOLID TUMORS, INCLUDING: * Glioblastoma (GBM)* * Medulloblastoma?? * Meningioma? . 45 Sources ‘ob (201) Curt Op
Slide 29: VBI-1901: Re-stimulated CD4+ and CD8+ T-cell Responses
VBI-1901: Re-stimulated CD4+ and CD8+ T-cell Responses in CMV-positive Human Subject Ex Vivo Fresh PBMCs stimulated with VBI-1901 vs recombinant antigens eVLPs rapidly restimulate both CD4+ & CD8+ T-cell responses eVLP presentation enhances stimulation relative to matched recombinant antigen Restimu
Slide 30: VBI-1901 Induction of CCL3 in Ex Vivo PBMCs
VBI-1901 Induction of CCL3 in Ex Vivo PBMCs from CMV-positive Healthy Subjects and Patients with Solid Tumors CCL3 Secretion Cs CCL3 Secretion (pg/ml) Strength of Response (% of total T cell response) % sy, & Sy <i & + PBMCs from CMV*+ healthy subjects or patients with GBM, medulloblastoma, or breas
Slide 31: GBM Phase I/IIa Clinical Study Overview
GBM Phase I/Ila Clinical Study Overview TRIAL DESIGN * Two-part, multi-center, open-label, dose-escalation study of VBI-1901 in patients with recurrent GBM (rGBM) * PartA: * Dose-escalation phase to define the safety, tolerability, and optimal dose level of VBI-1901 * N=upto 18 patients * First pati
Slide 32: 4. Summary
wm, =\Vie)ia 4. Summary Z SS aS Zs NASDAQ: VBIV 2
Slide 33: Value Proposition for VBI Vaccines
NNN 7 Value Proposition for VBI Vaccines KEY VALUE DRIVERS IN NEXT 18 MONTHS: Sci-B-Vac®: Phase III Program in the U.S., Europe, and Canada Enrollment initiated in Q4 2017, headline results expected mid-2019 CMV: Phase | Clinical Study Final results expected mid-2018 GBM: Phase I/Ila Clinical Study
Slide 34: VBI Vaccines Inc. contact details
Noy, \ y SS U S Zmpyy VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 [email protected] NASDAQ: VBIV